Kidney Diseases – Talk Bio

Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis

1 month ago talkbio0Tagged Apellis, Approved, C3 G, Fabhalta, Kidney Diseases, Novartis, pegcetacoplan, Proteinuria, United States Food and Drug Administration

Fabhalta, United States Food and Drug Administration, Apellis, Novartis, Approved, C3 G, Proteinuria, pegcetacoplan, Kidney Diseases

Metsera and Maze Therapeutics Raise $415 Million in Successful Biotech IPOs

3 months ago talkbio0Tagged biotech, Dosage Forms, IPOs, Kidney Diseases, Listings, Metsera, Nasdaq, Obesity

Biotech IPOs, Metsera, Maze Therapeutics, obesity treatment, kidney disease, NASDAQ listings, pharmaceutical funding

FDA Approves Ozempic for Reducing Kidney Disease Risks in Adults with Type 2 Diabetes and Chronic Kidney Disease

3 months ago talkbio0Tagged Agonist, Approved, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes, GLP-1 receptor, Kidney Diseases, Ozempic, Risk, semaglutide, United States Food and Drug Administration

Ozempic, FDA Approval, Type 2 Diabetes, Chronic Kidney Disease (CKD), Kidney Disease Risks, Cardiovascular Disease Risks, Semaglutide, GLP-1 Receptor Agonist

Maze Therapeutics Secures $115 Million Series D Funding to Advance Clinical-Stage Kidney Disease Programs

5 months ago talkbio0Tagged amsacrine/azacitidine/etoposide, APOL1 gene, Chronic Kidney Diseases, clinical-stage programs, Kidney Diseases, MZE782, MZE829, Precision Medicine, Series

Maze Therapeutics, Series D funding, kidney disease, clinical-stage programs, precision medicine, APOL1 kidney disease, chronic kidney disease, MZE829, MZE782.

Novo Nordisk Terminates Development of Kidney Disease Drug Ocedurenone After Phase 3 Failure

6 months ago talkbio0Tagged CLARION-CKD, Drug Development, Failure (biologic function), Hypertensive disease, Kidney Diseases, Nordisk, Ocedurenone, Phase 3 trial

Novo Nordisk, ocedurenone, kidney disease, hypertension, Phase 3 trial, CLARION-CKD, drug development failure

GSK and Cambridge University Collaborate on $65M Research Initiative to Combat Immune-Related Kidney and Lung Diseases

6 months ago talkbio0Tagged Cambridge University, immune-related diseases, Kidney Diseases, Lung diseases, SmithKline Beecham

GSK, Cambridge University, Immune-related diseases, Kidney diseases, Lung diseases, Research collaboration, $65M deal

Otsuka Seeks Accelerated Approval for Sibeprenlimab in IgA Nephropathy Following Positive Phase III Interim Results

6 months ago talkbio0Tagged Accelerated, Antibodies, Approved, Autoimmune Diseases, IGA Glomerulonephritis, Kidney Diseases, Otsuka, Phase 3 Clinical Trials, Sibeprenlimab, TNFSF13 protein, human, United States Food and Drug Administration

Otsuka, sibeprenlimab, IgA nephropathy, Phase III trial, accelerated approval, FDA, kidney disease, autoimmune disease, APRIL antibody.

Purespring Therapeutics Secures £80M ($105M) Series B Funding to Advance IgAN Gene Therapy into Clinical Trials

7 months ago talkbio0Tagged AAVS1 gene, Clinical Trials, gene therapy, glomerular kidney disease, IGA Glomerulonephritis, Kidney Diseases, Nephrotic Syndrome, Podocytes, Purespring, Series B

Purespring Therapeutics, IgAN gene therapy, kidney disease, Series B funding, clinical trials, AAV gene therapy, podocytes, nephrotic syndrome, glomerular kidney disease.